This inventor holds 4 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Daiichi Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited. Active years: 1999-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Tokyo, JP (1999 - 2000)
- Shimada, JP (2015 - 2017)
Company Filing History:

Years Active: 1999-2017
Title: Shinji Sagasaki: Innovator in Pharmaceutical Composition
Introduction
Shinji Sagasaki is a notable inventor based in Shimada, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 4 patents. His work focuses on developing pharmaceutical compositions that exhibit satisfactory dissolution properties across a wide pH range.
Latest Patents
Sagasaki's latest patents include a pharmaceutical composition designed to provide a preparation that maintains effective dissolution properties. This composition is characterized by the inclusion of N-(5-chloropyridin-2-yl)-N-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, along with a pharmacologically acceptable salt or hydrate of this compound. Additionally, it contains one or more species selected from a group consisting of sugar alcohols and water-swelling additives.
Career Highlights
Throughout his career, Sagasaki has worked with prominent companies in the pharmaceutical industry, including Daiichi Pharmaceutical Co., Ltd. and Daiichi Sankyo Company, Limited. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Sagasaki has collaborated with notable colleagues such as Hiroaki Nakagami and Masazumi Kojima. These partnerships have likely enhanced his research and development efforts in the pharmaceutical sector.
Conclusion
Shinji Sagasaki is a distinguished inventor whose work in pharmaceutical compositions has the potential to impact the industry significantly. His innovative approaches and collaborations reflect his commitment to advancing pharmaceutical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile